×
About 30,262 results

ALLMedicine™ B-cell Lymphoma Center

Research & Reviews  14,383 results

Impact of Hypoalbuminemia on the Prognosis of Relapsed/Refractory B-Cell Lymphoma Treat...
https://doi.org/10.1111/ejh.13609
European Journal of Haematology; Melody M, Gandhi S et. al.

Mar 3rd, 2021 - Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if Axicabtagene Ciloleucel (axi-cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B-cell lymphoma. We conducted a retr...

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformatio...
https://doi.org/10.1038/s41375-021-01181-w 10.3109/10428194.2014.979411 10.1182/blood-2018-01-791376 10.1182/blood-2013-03-489518 10.1182/bloodadvances.2016003632 10.1053/j.seminoncol.2016.02.012 10.3324/haematol.2019.224121 10.1084/jem.20131448 10.1182/bloodadvances.2017007302 10.1309/AJCPATRQWANW2O3N 10.1111/bjh.15514 10.1200/JCO.2016.70.4320 10.1182/asheducation-2018.1.256 10.1182/blood-2017-02-765685 10.1111/bjh.14700 10.1002/ajh.23841 10.1038/s41591-018-0016-8 10.1182/blood-2017-11-764332 10.1056/NEJMoa1801445 10.1016/j.cell.2016.12.013 10.1016/j.molcel.2014.05.016 10.1158/2159-8290.CD-17-0605 10.1093/nar/gku449 10.1016/j.molcel.2017.06.004 10.1186/s13045-019-0757-y 10.1016/j.cell.2013.03.036 10.1038/onc.2013.179 10.1182/blood-2015-04-639542 10.1126/scitranslmed.aav5599 10.1182/blood.2018893982 10.1182/blood.2019002922 10.1016/j.ccr.2013.11.003 10.1038/s41467-019-09645-5 10.1016/j.ccell.2018.11.001 10.1056/NEJMoa1513257 10.1038/nm.3435 10.1158/2159-8290.CD-14-0098 10.1182/blood-2012-05-423194 10.1182/blood-2015-03-585075 10.1182/blood-2011-05-356063 10.1038/nature16979 10.1038/leu.2017.207 10.1038/nm.4378 10.1016/j.molcel.2018.06.036 10.1073/pnas.1608319113 10.1038/leu.2015.142 10.1016/j.leukres.2018.07.025 10.1158/0008-5472.CAN-16-1793 10.1158/0008-5472.CAN-12-3709 10.1038/nature15395 10.1038/nature14666 10.1016/j.cell.2012.08.026
Leukemia Fiskus W, Mill CP et. al.

Mar 3rd, 2021 - Richter Transformation (RT) develops in CLL as an aggressive, therapy-resistant, diffuse large B cell lymphoma (RT-DLBCL), commonly clonally-related (CLR) to the concomitant CLL. Lack of available pre-clinical human models has hampered the develop...

Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma.
https://doi.org/10.1080/10428194.2021.1891233
Leukemia & Lymphoma; Fang X, Young KH

Mar 2nd, 2021 - Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma.|2021|Fang X,Young KH,|

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: result...
https://doi.org/10.1182/bloodadvances.2020002690
Blood Advances; Kostakoglu L, Martelli M et. al.

Mar 2nd, 2021 - GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). ...

Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene cilole...
https://doi.org/10.1002/cam4.3664
Cancer Medicine; Hoogland AI, Jayani RV et. al.

Feb 28th, 2021 - Chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel (axi-cel) has considerably improved survival in adults with relapsed/refractory large B-cell lymphoma. This study reports patient-reported outcomes (PROs) such as quality of lif...

see more →

Guidelines  57 results

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm
https://ascopubs.org/doi/full/10.1200/JCO.20.01501
Journal of Clinical Oncology; Crombie JL

Aug 19th, 2020 - We briefly describe the new genomic categories, highlighting both their potential to profoundly transform the approach to DLBCL treatment and the significant challenges this will entail.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 7th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Novel CAR-T Cell Therapy Combination Shows Preliminary Activity in R/R B-cell Lymphoma
https://www.targetedonc.com/view/novel-car-t-cell-therapy-combination-shows-preliminary-activity-in-r-r-b-cell-lymphoma

May 28th, 2020 - First-in-human findings show that ALLO-501, an allogeneic chimeric antigen receptor (CAR)-T cell therapy plus ALLO-647, a monoclonal antibody, has clinical activity and is tolerable in patients with relapsed/refractory large B-cell or follicular l...

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192083/
Leukemia Research; Paneesha S

Apr 29th, 2020 - The global pandemic of the novel coronavirus SARS-CoV-2 represents one of the greatest infectious challenges to human health in recent history. At the current time over 3.2 million people have been infected and this has proved fatal in over 230,00...

The effect of COVID-19 on the management of patients with lymphoma
https://lymphomahub.com/medical-information/the-effect-of-covid-19-on-the-management-of-patients-with-lymphoma
Lymphoma Hub;

Mar 23rd, 2020 - The whole medical community is living in an extraordinary and unexpected time, facing the SARS-CoV-2 pandemic. Every medical specialty is currently defining measures and guidelines to manage the risk of infection among patients and during therapy ...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  15,025 results

Impact of Hypoalbuminemia on the Prognosis of Relapsed/Refractory B-Cell Lymphoma Treat...
https://doi.org/10.1111/ejh.13609
European Journal of Haematology; Melody M, Gandhi S et. al.

Mar 3rd, 2021 - Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if Axicabtagene Ciloleucel (axi-cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B-cell lymphoma. We conducted a retr...

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformatio...
https://doi.org/10.1038/s41375-021-01181-w 10.3109/10428194.2014.979411 10.1182/blood-2018-01-791376 10.1182/blood-2013-03-489518 10.1182/bloodadvances.2016003632 10.1053/j.seminoncol.2016.02.012 10.3324/haematol.2019.224121 10.1084/jem.20131448 10.1182/bloodadvances.2017007302 10.1309/AJCPATRQWANW2O3N 10.1111/bjh.15514 10.1200/JCO.2016.70.4320 10.1182/asheducation-2018.1.256 10.1182/blood-2017-02-765685 10.1111/bjh.14700 10.1002/ajh.23841 10.1038/s41591-018-0016-8 10.1182/blood-2017-11-764332 10.1056/NEJMoa1801445 10.1016/j.cell.2016.12.013 10.1016/j.molcel.2014.05.016 10.1158/2159-8290.CD-17-0605 10.1093/nar/gku449 10.1016/j.molcel.2017.06.004 10.1186/s13045-019-0757-y 10.1016/j.cell.2013.03.036 10.1038/onc.2013.179 10.1182/blood-2015-04-639542 10.1126/scitranslmed.aav5599 10.1182/blood.2018893982 10.1182/blood.2019002922 10.1016/j.ccr.2013.11.003 10.1038/s41467-019-09645-5 10.1016/j.ccell.2018.11.001 10.1056/NEJMoa1513257 10.1038/nm.3435 10.1158/2159-8290.CD-14-0098 10.1182/blood-2012-05-423194 10.1182/blood-2015-03-585075 10.1182/blood-2011-05-356063 10.1038/nature16979 10.1038/leu.2017.207 10.1038/nm.4378 10.1016/j.molcel.2018.06.036 10.1073/pnas.1608319113 10.1038/leu.2015.142 10.1016/j.leukres.2018.07.025 10.1158/0008-5472.CAN-16-1793 10.1158/0008-5472.CAN-12-3709 10.1038/nature15395 10.1038/nature14666 10.1016/j.cell.2012.08.026
Leukemia Fiskus W, Mill CP et. al.

Mar 3rd, 2021 - Richter Transformation (RT) develops in CLL as an aggressive, therapy-resistant, diffuse large B cell lymphoma (RT-DLBCL), commonly clonally-related (CLR) to the concomitant CLL. Lack of available pre-clinical human models has hampered the develop...

Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma.
https://doi.org/10.1080/10428194.2021.1891233
Leukemia & Lymphoma; Fang X, Young KH

Mar 2nd, 2021 - Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma.|2021|Fang X,Young KH,|

Clear Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
https://www.medscape.com/viewarticle/946711

Mar 2nd, 2021 - NEW YORK (Reuters Health) - Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favo...

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: result...
https://doi.org/10.1182/bloodadvances.2020002690
Blood Advances; Kostakoglu L, Martelli M et. al.

Mar 2nd, 2021 - GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). ...

see more →

News  777 results

Clear Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
https://www.medscape.com/viewarticle/946711

Mar 2nd, 2021 - NEW YORK (Reuters Health) - Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favo...

FDA OKs New CAR T- Cell Tx for Large B-cell Lymphomas
https://www.medscape.com/viewarticle/945417

Feb 4th, 2021 - The US Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi), a chimeric antigen receptor (CAR) T-cell product for the treatment of adults with certain types of relapsed or refractory large B-cell lymphoma who relapse...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

B-cell Lymphoma Might Respond to N-myristoyltransferase Inhibition
https://www.medscape.com/viewarticle/941669

Nov 26th, 2020 - NEW YORK (Reuters Health) - Targeting N-myristoylation might prove to be an effective treatment for B-cell lymphoma and other cancers, according to a preclinical study. Myristoylation, the N-terminal modification of proteins mediated by N-myristoy...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

see more →

Patient Education  5 results see all →